Heron Therapeutics (HRTX) Tops Q3 EPS by 12c

Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.17), $0.12 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $31.43 million versus the consensus estimate of $32.75 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business
• OMNIQ Corp. posts Q2 2026 revenue of $7.4M, widens net loss